RESUMO
BACKGROUND: Coeliac disease (CD) is an autoimmune disorder strongly associated with Human Leukocyte Antigen (HLA) genes DQ2 and DQ8. These alleles are also associated with other autoimmune diseases including type 1 dia-betes (T1D) and these patients are consequently at a higher risk of developing CD. We examined the frequency of high-risk HLA alleles in a cohort of South African T1D pediatric patients. METHODS: A total of 22 pediatric participants were recruited at an endocrinology clinic in a public sector hospital in Johannesburg, South Africa. Clinical details were collected, and all patients were HLA typed at the DQ loci. RESULTS: Of our T1D patients, 63.6% had at least 1 high-risk HLA type alleles associated with CD. Of the patients with high-risk alleles, DQ2 was found in the majority which is consistent with CD literature. CONCLUSIONS: This study provides preliminary insight into the frequency of the HLA-DQ types associated with CD in a South African population. The high prevalence of high-risk alleles in our T1D population motivates continual monitoring and further investigations into CD in South Africa.
Assuntos
Doença Celíaca , Diabetes Mellitus Tipo 1 , Humanos , Criança , Diabetes Mellitus Tipo 1/diagnóstico , Diabetes Mellitus Tipo 1/genética , Diabetes Mellitus Tipo 1/complicações , África do Sul , Alelos , Doença Celíaca/genética , Doença Celíaca/complicações , Teste de Histocompatibilidade , Predisposição Genética para DoençaRESUMO
Antibody tests for the novel coronavirus, SARS-CoV2, have been developed both as rapid diagnostic assays and for high-throughput formal serology platforms. Although these tests may be a useful adjunct to a diagnostic strategy, they have a number of limitations. Because of the antibody and viral dynamics of the coronavirus, their sensitivity can be variable, especially at early time points after symptom onset. Additional data are required on the performance of the tests in the South African population, especially with regard to development and persistence of antibody responses and whether antibodies are protective against reinfection. These tests may, however, be useful in guiding the public health response, providing data for research (including seroprevalence surveys and vaccine initiatives) and development of therapeutic strategies.
Assuntos
Betacoronavirus , Técnicas de Laboratório Clínico , Infecções por Coronavirus , Testes Imunológicos/métodos , Pandemias , Pneumonia Viral , Testes Sorológicos/métodos , Betacoronavirus/genética , Betacoronavirus/imunologia , Betacoronavirus/isolamento & purificação , COVID-19 , Teste para COVID-19 , Técnicas de Laboratório Clínico/métodos , Técnicas de Laboratório Clínico/normas , Infecções por Coronavirus/diagnóstico , Infecções por Coronavirus/epidemiologia , Infecções por Coronavirus/imunologia , Humanos , Pneumonia Viral/diagnóstico , Pneumonia Viral/epidemiologia , Pneumonia Viral/imunologia , Reprodutibilidade dos Testes , SARS-CoV-2 , Sensibilidade e Especificidade , Estudos Soroepidemiológicos , África do Sul/epidemiologiaRESUMO
Antibody tests for the novel coronavirus, SARS-CoV2, have been developed both as rapid diagnostic assays and for high-throughput formal serology platforms. Although these tests may be a useful adjunct to a diagnostic strategy, they have a number of limitations. Because of the antibody and viral dynamics of the coronavirus, their sensitivity can be variable, especially at early time points after symptom onset. Additional data are required on the performance of the tests in the South African population, especially with regard to development and persistence of antibody responses and whether antibodies are protective against reinfection. These tests may, however, be useful in guiding the public health response, providing data for research (including seroprevalence surveys and vaccine initiatives) and development of therapeutic strategies
